-
Oral Semaglutide Reduces HbA1c, Weight in Patients With T2DM
drugs
August 01, 2019
Compared with placebo, oral semaglutide monotherapy is associated with superior and clinically relevant improvements in glycated hemoglobin (HbA1c) ...
-
Application to EMA filed for the approval of oral semaglutide
europeanpharmaceuticalreview
April 30, 2019
It has been announced that a Marketing Authorisation Application (MAA) has been submitted to the European Medicines Agency (EMA) for oral semaglutide.
-
Novo Nordisk boosts its GLP-1 score with yet more evidence for crucial semaglutide pill
fiercepharma
October 29, 2018
Novo Nordisk rolled out its latest set of data for its next great hope: the oral version of semaglutide, which would become the only pill in the increasingly competitive GLP-1 class.
-
Novo's semaglutide hits the mark in Phase 3 type 2 diabetes study
pharmafile
August 22, 2018
Novo Nordisk has revealed new Phase 3a data on its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide in the treatment of adult patients with type 2 diabetes and moderate renal impairment......
-
Novo has a big pricing decision to make with semaglutide. Which way will it go?
fiercepharma
August 14, 2018
As Novo Nordisk’s highly anticipated semaglutide pill nears the market, the company has a big decision to make: at what price?
-
Novo’s oral semaglutide bests MSD’s Januvia on HbA1c reduction
pharmatimes
July 05, 2018
Novo Nordisk has presented data from a Phase IIIa study showing that an oral formulation of its GLP-1 analogue semaglutide was better at reducing blood sugar than MSD’s DPP-4 inhibitor Januvia in patients with type II diabetes.
-
Novo Nordisk's oral semaglutide impresses analysts against Victoza, Januvia
fiercepharma
June 25, 2018
Once it wins approval, Novo Nordisk’s highly anticipated oral diabetes drug semaglutide will go up against some stiff competition. But the drugmaker just showed that its up-and-comer can take the heat.
-
Semaglutide may help people with obesity lose weight
europeanpharmaceuticalreview
March 22, 2018
A compound that mimics a naturally occurring hormone that regulates appetite may help people who have obesity but not diabetes to lose weight…
-
Novo Nordisk’s diabetes pill presents the first successful data
biospectrumasia
February 27, 2018
The oral form of the drug, known generically as semaglutide, is crucial for ensuring the group's long-term growth, as price pressure mounts in a crowded market targeting the world's 450 million diabetics.
-
Semaglutide Demonstrated Significant Reductions in Blood Sugar and Weight Compared with Dulaglutide;
prnasia
February 02, 2018
The Lancet Diabetes and Endocrinology has published the results of the SUSTAIN 7 trial